Larssonmcknight1703

The L ↔ Al + Al11Ce3 technologically important eutectic transformation in Al-Ce binary alloys, containing from 5 to 20 wt.% Ce and ranging from hypo- to hypereutectic compositions, was examined along with the microstructure and properties of its solidified product. A combination of thermal analysis and metallography determined the coordinates of the eutectic point at 644.5 ± 0.6 °C and 10.6 wt.% Ce, clarifying the existing literature ambiguity. Despite the high entropy of melting of the Al11Ce3 phase, in hypoeutectic alloys the eutectic was dominated by the regular morphology of periodically arranged lamellae, typical for non-faceted systems. In the lamellar eutectic, however, the faceting of Al11Ce3 was identified at the atomic scale. In contrast, for hypereutectic compositions, the Al11Ce3 eutectic phase exhibited complex morphology, influenced by the proeutectic Al11Ce3 phase. selleck The Al11Ce3 eutectic phase lost its coherency with Al; it was deduced that a partial coherency was present only at early stages of lamellae growth. The orientation relationships between the Al11Ce3 and Al in the eutectic structure, leading to partial coherency, were determined to be Al ║ Al11Ce3 with Al ║ Al11Ce3 and Al ║ Al11Ce3 with Al ║ Al11Ce3. The Al11Ce3 phase with a hardness of 350 HV and Al matrix having 35 HV in their eutectic arrangement formed in situ composite, with the former playing a role of reinforcement. However, the coarse and mostly incoherent Al11Ce3 eutectic phase provided limited strengthening and the Al-Ce alloy consisting of 100% eutectic reached at room temperature a yield stress of just about 70 MPa.Immunoassays are developed based on antigen-antibody interactions. A mimotope is an effective recognition receptor used to study the mechanism of action of antigens and antibodies, and is used for improving the sensitivity of the antibody. In this study, we built a 3D structure of the citrinin (CIT) mimotope X27 and anti-CIT single-chain antibody fragment (ScFv) through a "homologous modeling" strategy. Then, CIT and X27 were respectively docked to anti-CIT ScFv by using the "molecular docking" program. Finally, T28, F29, N30, R31, and Y32 were confirmed as the key binding sites in X27. Furthermore, the result of the phage-ELISA showed that the mutational phage lost the binding activity to the anti-CIT ScFv when the five amino acids were mutated to "alanine", thereby proving the correctness of the molecular docking model. Lastly, a site-directed saturation strategy was adopted for the sites (T28, F29, N30, R31, and Y32). Eighteen different amino acids were introduced to each site on average. The activities of all mutants were identified by indirect competitive ELISA. The sensitivities of mutants T28F, T28I, F29I, F29V, N30T, and N30V were 1.83-, 1.37-, 1.70-, 2.96-, 1.31-, and 2.01-fold higher than that of the wild-type, respectively. In conclusion, the binding model between the CIT and antibody was elaborated for the first time based on the mimotope method, thereby presenting another strategy for improving the sensitivity of citrinin detection in immunoassays.The heterogeneity of colon cancers and their reactions presents both a challenge and promise for personalized medicine. The challenge is to develop effective biologically personalized therapeutics guided by predictive and prognostic biomarkers. Presently, there are several classes of candidate biomarkers, including genomic probes, inhibitory RNAs, assays for immunity dysfunction and, not to be forgotten, specific histopathologic and histochemical features. To develop effective therapeutics, candidate biomarkers must be qualified and validated in comparable independent cohorts, no small undertaking. This process and subsequent deployment in clinical practice involves not only the strong association of the biomarker with the treatment but also careful attention to the prosaic aspects of representative tumor site selection, obtaining a fully adequate sample which is preserved and prepared to optimize high quality analysis. In the future, the clinical utility of biomarker analytical results will benefit from associated clinical and basic science data with the assistance of artificial intelligence techniques. By application of an individualized, selected suite of biomarkers, comprehensively interpreted, individualized, more effective and less toxic therapy for colon cancer will be enabled, thereby fulfilling the promise of personalized medicine.We studied the microstructures and isothermal oxidation of the Nb-silicide-based alloys Nb-11.5Ti-18Si-5Mo-2W-4.9Sn-4.6Ge-4.5Cr-4.7Al-1Hf (JZ4) and Nb-21Ti-18Si-6.7Mo-1.2W-4.4Sn-4.2Ge-4Cr-3.7Al-0.8Hf (JZ5), calculated their average creep rate for the creep goal conditions of T = 1200 °C and σ = 170 MPa, and compared properties of the two alloys with those of other refractory metal (RM) complex concentrated alloys (RCCAs). Both alloys had a density less than 7.3 g/cm3 and lower than the density of multiphase bcc solid solution + M5Si3 silicide RCCAs. There was macrosegregation of Si in both alloys, which had the same phases in their as-cast microstructures, namely βNb5Si3, αNb5Si3, A15-Nb3X (X = Al, Ge, Si, Sn), TM5Sn2X (X = Al, Ge, Si), C14-Cr2Nb, but no solid solution. After heat treatment at 1500 °C for 100 h, a low volume fraction of a W-rich (Nb, W)ss solid solution was observed in both alloys together with βNb5Si3, αNb5Si3 and A15-Nb3X but not the TM5Sn2X, whereas the Laves phase was observed only in JZ4. At 800 °C, both alloys did not pest, and there was no spallation of their scales at 1200 °C. At both temperatures, both alloys followed parabolic oxidation kinetics and their weight changes were lower than those of Ti-rich Nb-silicide-based alloys. The oxidation of both alloys was superior to that of other RCCAs studied to date. For each alloy the Si macrosegregation, volume fraction of solid solution, chemical composition of solid solution and Nb5Si3, and weight changes in isothermal oxidation at 800 and 1200 °C that were calculated using the alloy design methodology NICE agreed well with the experimental results.